Latest News
Second Sigmoid Study Ups Early Cancer Detection
Feb 03, 2012
Repeat flexible sigmoidoscopy increased detection of colorectal cancer or advanced adenoma by one-fourth in women and one-third in men, according to the latest results from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Among nearly 78,000 enrollees, the second flexible sigmoidoscopy exam increased the screening yield by 26% in women, 34% in men, and 32% overall, reported Joel L. Weissfeld, MD, MPH, from the University of Pittsburgh Medical Center, and colleagues in the Journal of the National Cancer Institute.
« More
- (Feb-02) - Chocolate shown to protect against colon cancer
- (Feb-02) - Drug Improves Survival of Colorectal Cancer Patients, Trial Results Show
- (Feb-02) - Colorectal cancer risk related to gene’s expression
- (Feb-02) - WORLD CANCER DAY MARKED WITH NEW CANADIAN SURVEY RESULTS SHOWING INCREASE IN COLON CANCER SCREENING
- (Feb-02) - Avastin May Help Colorectal Cancer Patients Live Longer, Study Shows
- (Feb-01) - Pitt Team Finds Protein That Keeps Balance Between Tumor Cell Growth and Suppression
- (Jan-26) - Drug Improves Survival of Colorectal Cancer Patients, Trial Results Show
- (Jan-23) - Exercise cuts bowel cancer risk
- News Archives...
 |
 |
 |
 |
 |
 |
|
Twitter |
Blog |
Youtube |
Membership |
Donate |
igive |
Upcoming Event
World Cancer Day 2012
February 4, 2012
On the 4th of February, 2011 UICC and its partner organizations ran 244 campaigns all over the world to raise awareness for a disease that causes millions of deaths every year, many of which could have been prevented.
More than ever before there is a need for a concerted and coordinated fight against cancer, and we believe that World Cancer Day can play its part by providing an even bigger platform for your cancer messages.
« More
Clinical Trials
Oncozyme Pharma
Jan 27, 2012
The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS in combination with standard of care for metastatic colorectal cancer subjects with disease progression following a first line treatment.
« More